Asher Biotherapeutics Revenue and Competitors

Location

$219M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Asher Biotherapeutics's estimated annual revenue is currently $2.9M per year.(i)
  • Asher Biotherapeutics's estimated revenue per employee is $77,500
  • Asher Biotherapeutics's total funding is $219M.

Employee Data

  • Asher Biotherapeutics has 37 Employees.(i)
  • Asher Biotherapeutics grew their employee count by -5% last year.

Asher Biotherapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Founder, CSOReveal Email/Phone
3
VP, Regulatory AffairsReveal Email/Phone
4
VP Translational Research and MedicineReveal Email/Phone
5
VP FinanceReveal Email/Phone
6
VP, Business and Commercial StrategyReveal Email/Phone
7
VP and Head CMCReveal Email/Phone
8
Director, Drug Substance Process DevelopmentReveal Email/Phone
9
Associate Director, Immune TargetingReveal Email/Phone
10
Chief Technology Officer, FounderReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.4M70-8%$53MN/A
#2
$32.4M167-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.8M1813%N/AN/A
#5
$0.8M5-50%N/AN/A
#6
$0.8M100%N/AN/A
#7
$14M90-12%N/AN/A
#8
$0.4M33610%$236.7MN/A
#9
$4.8M62-74%$160MN/A
#10
$3.7M24-8%N/AN/A
Add Company

What Is Asher Biotherapeutics?

We build immunotherapies.

keywords:N/A

$219M

Total Funding

37

Number of Employees

$2.9M

Revenue (est)

-5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Asher Biotherapeutics News

2022-04-06 - Asher Bio to Present New Preclinical Data Demonstrating ...

--(BUSINESS WIRE)--Asher Biotherapeutics (Asher Bio), a biotechnology company developing precisely-targeted immunotherapies for cancer,...

2022-04-06 - Lonza and Asher Biotherapeutics to Collaborate on Manufacturing ...

Lonza and Asher Biotherapeutics have entered a manufacturing agreement for a cis-targeted IL-2 fusion protein, AB359.

2022-04-06 - Lonza Will Manufacture Asher Bio's Cis-targeted IL-2 Fusion Protein

Asher Biotherapeutics, which is developing targeted immunotherapies for cancer, autoimmune, and infectious diseases, and Lonza, a CDMO,...

2021-09-01 - Asher Bio Raises $108M in Series B Funding

Asher Biotherapeutics, a South San Francisco CA-based biotechnology company, raised $108M in Series B funding. The round was led by Wellington Management Company LLP with participation from RA Capital Management, Janus Henderson Investors, Logos Capital, Marshall Wace, Alexandria Venture Invest ...

2021-09-01 - Asher Bio Closes $108 Million Series B Financing

Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the closing of an oversubscribed Series B financing, which raised $108 million. The financing was led by Wellington Management Company LLP ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.7M37-10%N/A
#2
$8.2M3815%N/A
#3
$7.5M38-5%$7.4M
#4
$5.5M3934%N/A
#5
$3.2M40-30%N/A